OBJECTIVE To determine the efficacy of clarithromycin in the treatment of Pityriasis Rosea (PR). STUDY DESIGN Double blind randomized controlled trial. PLACE AND DURATION OF STUDY Dermatology OPD, Military Hospital, Rawalpindi, from July 2008 to July 2009. METHODOLOGY Patients aged above 10 years, diagnosed with PR, were randomly assigned to two groups of 30 each to receive either clarith...

1 Dr K Shilpa, MBBS,MD (DVL), Assistant Professor 2 Dr B Leelavathy, MBBS, MD(DVL), Professor and Head 3 Dr K Kavya, MD, Junior Resident 4 Dr DV Lakshmi, DVD, Junior Resident 5 Dr G Divya, MBBS,MD(DVL), Senior Resident Department of Dermatology, Venereology, Leprology, Bangalore Medical College and Research Institute, Bangalore. KR Market, Bengaluru-560002, Karnataka, India Corresponding author...

Pityriasis rosea (PR) is an acute, self-limited papulosquamous dermatosis localized on the trunk and extremities, that affects otherwise healthy adolescents and young adults. Although the classic presentation is readily recognized, atypical forms may present a challenge. Many atypical forms of the disease have been reported in the literature.[1]We report two cases with atypical features. Involv...

Sir, A 74-year-old female patient treated with angiotensin-converting enzyme inhibitor for arterial hypertension metformin and atorvastatin insulin-independent diabetes mellitus hyperlipidemia, respectively, consulted the outpatient dermatological clinic a rash that appeared fifteen days prior to consultation. The received second dose of mRNA COVID-19 vaccine on July 29, 2021, was due receive t...

Pityriasis rosea (PR) is an acute, self-limiting papulosquamous exanthem. A number of atypical variants of PR, regarding morphology and distribution of the lesions or severity of the symptoms, may be observed. Herein, we present the first case of atypical PR with hypopigmented lesions and a target-shape herald patch.

reported to be as high as 69%.[1] Common cutaneous adverse effects include maculopapular eruptions and erythematous eruptions. Toxic epidermal necrolysis, Stevens–Johnson syndrome and acute generalized exanthematous pustulosis have also been reported with the use of imatinib. Other reported cutaneous adverse effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, purpur...